Next-Generation T-Cell Therapy for Solid Tumors
T-Knife CEO Thomas Soloway discusses the company's new approach to cell therapy, aiming to overcome the toughest barriers in the tumor microenvironment.
“We’re supercharging T cells to fight solid tumors”
In an interview with VC Magazin, Thomas Soloway explains how T-knife's next-generation T-cell platform is designed to tackle solid tumors. After a strategic refocus last year, the Berlin- and San Francisco-based company is entering a new phase in its mission.
T-Knife's Mission and Strategy
T-knife is preparing for its first-in-human Atlas Phase I trial, leveraging its transatlantic investor base and dual presence in Europe and the U.S. as key advantages.
- Next-generation T-cell platform to overcome tumor microenvironment barriers
- Strategic refocus to bring cell therapy to solid tumors
- First-in-human Atlas Phase I trial upcoming
Author's summary: T-knife develops supercharged T-cells to fight tumors.